UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~June~~November 1726, ~~2024~~2025

AccuStem Sciences Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

000-56257

87-3774438

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

5 Penn Plaza, 19^th Floor, #1954

New York, NY

10001

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: 00 44 2074952379

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 48.01 ~~Change~~Other ~~in Registrant’s Certifying Accountant~~Events.

OnAccustem ~~June~~Sciences ~~17,~~Inc.’s ~~2024,~~(the ~~Mercurius~~“Company”) ~~LLP~~MSC test (~~“Mercurius”~~MicroRNA Signature Classifier) ~~was~~is ~~appointed~~a non-invasive blood-based assay designed to assess the risk of lung cancer in people who qualify for low-dose computed tomography (LDCT) screening or have an indeterminate pulmonary nodule detected via imaging. It analyzes a panel of 24 circulating microRNAs (miRNAs) in plasma to classify nodules as ~~Accustem~~Low ~~Sciences,~~or ~~Inc~~High Risk for malignancy. This helps clinicians more accurately understand a patient’s cancer risk, potentially reducing unnecessary invasive procedures (~~the~~e.g., ~~“Company”~~biopsies or surgery) ~~independent registered~~for ~~public~~benign ~~accounting~~nodules ~~firm~~while prioritizing those at higher risk for further evaluation.

~~During~~In ~~the~~order ~~years~~to ~~ended~~establish ~~December~~reimbursement ~~31,~~for ~~2023~~the ~~and~~MSC ~~2022 and through June 17~~test, ~~2024,~~ the ~~date~~Company ~~the~~has ~~audit~~submitted ~~committee~~an ofapplication ~~the~~for ~~Board~~a ~~approved~~local ~~the~~coverage ~~engagement~~determination ofwith ~~Mercurius as the~~Novitas ~~Company’s~~Solutions ~~independent registered public accounting firm~~(“Novitas”), ~~neither~~a ~~the~~Medicare ~~Company~~Administrative ~~nor~~Contractor ~~anyone~~(MAC) onfor the ~~Company’s~~Centers ~~behalf~~for ~~consulted with~~Medicare ~~Mercurius~~& ~~regarding~~Medicaid Services (iCMS) for the ~~application~~JL ofregion, ~~accounting~~which ~~principles~~includes tothe aDistrict ~~specified~~of ~~transaction~~Columbia, ~~either~~Delaware, ~~completed or proposed~~Maryland, orNew ~~the type~~Jersey ~~of audit opinion that might be rendered on the Company’s financial statements,~~ and noPennsylvania. ~~written~~As ~~report~~part orof ~~oral~~this ~~advice was provided~~submission toprocess ~~the~~Novitas ~~Company~~has byinformed the Company that ~~the~~it ~~Company~~has ~~concluded~~determined ~~was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter~~ that ~~was either~~ the ~~subject~~application ~~of a disagreement, as that term~~ is ~~described~~complete inand ~~Item~~valid ~~304(a)(1)(iv)~~and ofwill ~~Regulation~~now ~~S-K~~enter ~~under~~ the ~~Exchange Act, or a reportable event, as that term is defined in Item 304(a)(1)(v)~~review ~~of Regulation S-K under the Exchange Act~~queue.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ACCUSTEM SCIENCES INC.
Date: December 30, 2024	By:	/s/ Wendy Blosser
Date: November 26, 2025	By:	/s/ Wendy Blosser
		Wendy Blosser
		Chief Executive Officer

-3-

Filing Compare · Accustem Sciences Inc.